Terms: = Pancreatic cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
119 results:
1. Undiagnosed RASopathies in infertile men.
Juchnewitsch AG; Pomm K; Dutta A; Tamp E; Valkna A; Lillepea K; Mahyari E; Tjagur S; Belova G; Kübarsepp V; Castillo-Madeen H; Riera-Escamilla A; Põlluaas L; Nagirnaja L; Poolamets O; Vihljajev V; Sütt M; Versbraegen N; Papadimitriou S; McLachlan RI; Jarvi KA; Schlegel PN; Tennisberg S; Korrovits P; Vigh-Conrad K; O'Bryan MK; Aston KI; Lenaerts T; Conrad DF; Kasak L; Punab M; Laan M
Front Endocrinol (Lausanne); 2024; 15():1312357. PubMed ID: 38654924
[TBL] [Abstract] [Full Text] [Related]
2. Activation of endogenous retroviruses and induction of viral mimicry by mek1/2 inhibition in pancreatic cancer.
Cortesi A; Gandolfi F; Arco F; Di Chiaro P; Valli E; Polletti S; Noberini R; Gualdrini F; Attanasio S; Citron F; Ho IL; Shah R; Yen EY; Spinella MC; Ronzoni S; Rodighiero S; Mitro N; Bonaldi T; Ghisletti S; Monticelli S; Viale A; Diaferia GR; Natoli G
Sci Adv; 2024 Mar; 10(13):eadk5386. PubMed ID: 38536927
[TBL] [Abstract] [Full Text] [Related]
3. The EIF3H-HAX1 axis increases RAF-MEK-ERK signaling activity to promote colorectal cancer progression.
Jin H; Huang X; Pan Q; Ma N; Xie X; Wei Y; Yu F; Wen W; Zhang B; Zhang P; Chen X; Wang J; Liu RY; Lin J; Meng X; Lee MH
Nat Commun; 2024 Mar; 15(1):2551. PubMed ID: 38514606
[TBL] [Abstract] [Full Text] [Related]
4. CENPL accelerates cell proliferation, cell cycle, apoptosis, and glycolysis via the mek1/2-ERK1/2 pathway in hepatocellular carcinoma.
He K; Xie M; Hong W; Li Y; Yin Y; Gao X; He Y; Chen Y; You C; Li J
Int J Biochem Cell Biol; 2024 Jan; 166():106481. PubMed ID: 37914022
[TBL] [Abstract] [Full Text] [Related]
5. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
6. Computational biology and in vitro studies for anticipating cancer-related molecular targets of sweet wormwood (Artemisia annua).
Dawood H; Celik I; Ibrahim RS
BMC Complement Med Ther; 2023 Sep; 23(1):312. PubMed ID: 37684586
[TBL] [Abstract] [Full Text] [Related]
7. Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma.
Sun T; Gilani S; Jain D; Cai G
Diagn Cytopathol; 2023 Nov; 51(11):674-683. PubMed ID: 37469257
[TBL] [Abstract] [Full Text] [Related]
8. The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer.
Entrialgo-Cadierno R; Cueto-Ureña C; Welch C; Feliu I; Macaya I; Vera L; Morales X; Michelina SV; Scaparone P; Lopez I; Darbo E; Erice O; Vallejo A; Moreno H; Goñi-Salaverri A; Lara-Astiaso D; Halberg N; Cortes-Dominguez I; Guruceaga E; Ambrogio C; Lecanda F; Vicent S
Mol Cancer; 2023 May; 22(1):86. PubMed ID: 37210549
[TBL] [Abstract] [Full Text] [Related]
9. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract] [Full Text] [Related]
10. 5'-tiRNA-Gln inhibits hepatocellular carcinoma progression by repressing translation through the interaction with eukaryotic initiation factor 4A-I.
Wu C; Liu D; Zhang L; Wang J; Ding Y; Sun Z; Wang W
Front Med; 2023 Jun; 17(3):476-492. PubMed ID: 36973570
[TBL] [Abstract] [Full Text] [Related]
11. MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition.
Silvis MR; Silva D; Rohweder R; Schuman S; Gudipaty S; Truong A; Yap J; Affolter K; McMahon M; Kinsey C
J Exp Med; 2023 Mar; 220(3):. PubMed ID: 36719686
[TBL] [Abstract] [Full Text] [Related]
12. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support pancreatic cancer Growth.
Erice O; Narayanan S; Feliu I; Entrialgo-Cadierno R; Malinova A; Vicentini C; Guruceaga E; Delfino P; Trajkovic-Arsic M; Moreno H; Valencia K; Blanco E; Macaya I; Öhlund D; Khatri P; Lecanda F; Scarpa A; Siveke JT; Corbo V; Ponz-Sarvise M; Vicent S
Clin Cancer Res; 2023 Mar; 29(6):1137-1154. PubMed ID: 36607777
[TBL] [Abstract] [Full Text] [Related]
13. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center.
Zhang XP; Xu S; Zhao ZM; Liu Q; Zhao GD; Hu MG; Tan XL; Liu R
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):140-146. PubMed ID: 36171169
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in pancreatic Adenocarcinoma.
Duan Y; Du Y; Gu Z; Zheng X; Wang C
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142223
[TBL] [Abstract] [Full Text] [Related]
15. Elevated Notch-1 expression promotes the lymph node metastasis of gastric cancer and the Notch-1-PTEN-ERK1/2 signalling axis promotes the progression of gastric cancer.
Ma H; Li N; Mo Z
Cytokine; 2022 Nov; 159():156013. PubMed ID: 36067712
[TBL] [Abstract] [Full Text] [Related]
16. DSCN: Double-target selection guided by CRISPR screening and network.
Liu E; Wu X; Wang L; Huo Y; Wu H; Li L; Cheng L
PLoS Comput Biol; 2022 Aug; 18(8):e1009421. PubMed ID: 35984840
[TBL] [Abstract] [Full Text] [Related]
17. Protein expression profiling identifies a prognostic model for ovarian cancer.
Xiong L; Tan J; Feng Y; Wang D; Liu X; Feng Y; Li S
BMC Womens Health; 2022 Jul; 22(1):292. PubMed ID: 35840928
[TBL] [Abstract] [Full Text] [Related]
18. KIF22 Promotes Development of pancreatic cancer by Regulating the MEK/ERK/P21 Signaling Axis.
Zhang R; Ma L; Wei Y; Wei K; Song T; Du Z; Feng Z
Biomed Res Int; 2022; 2022():6000925. PubMed ID: 35578724
[TBL] [Abstract] [Full Text] [Related]
19. Anticancer drug resistance: An update and perspective.
Nussinov R; Tsai CJ; Jang H
Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
[TBL] [Abstract] [Full Text] [Related]
20. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report.
Ardalan B; Azqueta JI; England J; Eatz TA
Cold Spring Harb Mol Case Stud; 2021 Oct; 7(5):. PubMed ID: 34667063
[TBL] [Abstract] [Full Text] [Related]
[Next]
